Food Allergy Research

Through our association with UT Southwestern, the Food Allergy Center at Children’s Health℠ is the only institution in North Texas conducting instrumental, groundbreaking research to develop new therapies for children with food allergies.

Food allergies affect more than 32 million Americans, including more than 5.6 million children under the age of 18. Symptoms of an allergic reaction can range from mild to anaphylaxis, a life-threatening condition that can cause death. Currently, there is no cure for food allergies and no treatments approved for general use.

The purpose of food allergy research is to better understand the causes of food allergy and to develop treatments that prevent severe allergic reactions. We hope that our efforts will one day lead to a cure for food allergies.

Clinical Research Studies

As the only academic-affiliated pediatric food allergy center in North Texas, we participate in numerous food allergy research studies including 12 ongoing IRB-approved projects. The majority of our research focuses on development of therapeutics for treatment of life-threatening food allergies, such as peanut allergy, milk allergy and others. We also participate in clinical trials investigating therapeutics for eosinophilic esophagitis.

See a list of all active clinical trials

Interested in joining a food allergy clinical trial?

Participation in research studies is influenced by interest level. If you would like to be a part of a future clinical trial, please enter your information in the Food Allergy Center Clinical Trial database, and our staff may contact you if we have an applicable study.

For more information on open clinical trials, contact our clinical research coordinators at foodallergyresearch@childrens.com. 

Research Highlights

Research at the Food Allergy Center includes participation in:

  • An NIH-sponsored trial investigating a potential therapeutic approach to treating children with multiple food allergies
  • Aimmune Therapeutics Phase 2 and 3 peanut oral immunotherapy studies
  • DBV Technologies Phase 2 and 3 peanut epicutaneous immunotherapy trials, Phase 2 milk epicutaneous immunotherapy trial and Phase 3 peanut EPIT trial in children 1 to 3 years
  • Astellas Phase 1 trial investigating a new medication for treatment of peanut allergy
  • Regeneron Phase 3 trial investigating a new medication for treatment of eosinophilic esophagitis (EoE)
  • Food Allergy Research & Education (FARE) Phase 2 trial peanut sublingual immunotherapy trial
  • Investigation of the microbiome and immune profile of patients with FPIES through the Miller Family Foundation
  • Numerous studies in collaboration with partners such as:
    • University of Arkansas for Medical Sciences; Little Rock, AR
    • Icahn School of Medicine at Mount Sinai; New York City, NY
    • University of North Carolina School of Medicine; Chapel Hill, NC
    • Johns Hopkins School of Medicine; Baltimore, MD
    • Massachusetts General Hospital; Boston, MA
    • National Jewish Health; Denver, CO
    • Stanford University; Stanford, CA
    • Children’s Hospital of Philadelphia; Philadelphia, PA
    • Emory Children’s; Atlanta, GA

Allergy and Immunology Training Program

The Allergy and Immunology Training Program at UT Southwestern, directed by David Khan, M.D., offers a diversity of clinical experiences in Allergy and Immunology. Learn more about the training program and its clinical and research applications at the Food Allergy Center at Children’s Health.

 

Share:
Linked In Email